uniQure/$QURE
1D1W1MYTD1Y5YMAX
Capital at risk
About uniQure
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
- Ticker
- $QURE
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 221
- Headquarters
- Amsterdam, Netherlands
- Website
- www.uniqure.com
uniQure Metrics
BasicAdvanced
$3.1B
-
-$4.04
0.94
-
Price and volume
Market cap
$3.1B
Beta
0.94
52-week high
$71.50
52-week low
$8.73
Average daily volume
1.1M
Financial strength
Current ratio
10.01
Quick ratio
9.792
Long term debt to equity
1.695
Total debt to equity
1.704
Interest coverage (TTM)
-3.31%
Profitability
EBITDA (TTM)
-182.916
Gross margin (TTM)
-614.33%
Net profit margin (TTM)
-1,350.73%
Operating margin (TTM)
-1,057.10%
Effective tax rate (TTM)
-2.87%
Revenue per employee (TTM)
$80,000
Management effectiveness
Return on assets (TTM)
-15.72%
Return on equity (TTM)
-157.61%
Valuation
Price to revenue (TTM)
151.524
Price to book
9.69
Price to tangible book (TTM)
13.23
Price to free cash flow (TTM)
-17.524
Free cash flow yield (TTM)
-5.71%
Free cash flow per share (TTM)
-2.584
Growth
Revenue change (TTM)
30.24%
Earnings per share change (TTM)
4.80%
3-year revenue growth (CAGR)
-44.95%
10-year revenue growth (CAGR)
1.37%
3-year earnings per share growth (CAGR)
0.66%
10-year earnings per share growth (CAGR)
0.91%
What the Analysts think about uniQure
Analyst ratings (Buy, Hold, Sell) for uniQure stock.
Analyst projections of the future price of uniQure stock.
Bulls say / Bears say
FDA agreed that the 3-year analysis from its Phase I/II Huntington’s disease trial could serve as the primary basis for an accelerated Biologics License Application filing for AMT-130, clearing the path for a U.S. approval submission in Q3 2026. (Reuters)
uniQure reported Q2 2026 revenue of $5.8 million, a 9.4% year-over-year increase, surpassing analysts’ consensus of $5.49 million, driven by higher license income. (Reuters via Investing.com)
The company raised $259 million in a follow-on equity offering in July 2026, extending its cash runway into 2030 to fund the anticipated commercial launch of AMT-130 and continued pipeline investment. (uniQure SEC filing)
An FDA official stated that uniQure’s Huntington’s disease gene therapy trial design did not demonstrate sufficient efficacy and recommended a new sham-controlled Phase III study, potentially delaying development and increasing R&D costs. (Reuters)
Adjusted earnings per share for Q2 2026 were a loss of $1.22, missing the consensus forecast of a $0.84 loss, reflecting widening operating losses and cost pressures. (Reuters via Investing.com)
uniQure’s Q2 net loss widened to $81.06 million, dwarfing its $5.84 million in revenue and underscoring substantial cash burn and liquidity sustainability risks. (S&P Capital IQ via MarketScreener)
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2026.
uniQure Financial Performance
Revenues and expenses
uniQure Earnings Performance
Company profitability
Upcoming events
No upcoming events
uniQure News
AllArticlesVideos
Funds containing uniQure
AllEURUSDGBP
Fund name | Fund size | $QURE weighting |
|---|---|---|
iShares Ageing Population€AGED | €822M | 0.23% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.20% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.20% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.03% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.